Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes
Mathias Jachs(Medical University of Vienna), Thomas Reiberger(Harvard University), Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Philipp Schwabl(Medical University of Vienna), Dunja Schaufler(Medical University of Vienna), Christopher Desbalmes(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Harvard University), Rafael Paternostro(Medical University of Vienna), Ernst Eigenbauer(Medical University of Vienna), Theresa Bucsics(Medical University of Vienna), Albert Friedrich Stättermayer(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Michael Trauner(Medical University of Graz), David Bauer(Austrian Academy of Sciences)
Cited by 98
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287